In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
- Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIs
~ Rivoceranib in Combination with Nivolumab Demonstrates Encouraging Anti-Tumor Activity and Favorable Tolerability in Patients with Unresectable or Metastatic Cancer ~